Core Viewpoint - The article discusses the significant advancements in the treatment of nasopharyngeal carcinoma (NPC) through the use of immune therapies like PD-1 inhibitors, highlighting the shift in focus from merely improving efficacy to enhancing safety and quality of life for patients [3][5]. Group 1: Clinical Trial Insights - The PLATINUM trial, a phase 2 clinical study, investigates the combination of nivolumab with chemotherapy and radiotherapy while omitting the traditional concurrent cisplatin treatment, focusing on patient-reported outcomes (PRO) [4][9]. - The study reveals that radiotherapy is the primary cause of decreased quality of life in patients, with specific symptoms such as appetite loss, speech, and swallowing difficulties being critical for assessing disease recurrence and social reintegration [4][10]. Group 2: Patient-Reported Outcomes - The research emphasizes the need for a comprehensive evaluation of cancer treatments that prioritizes patient quality of life alongside efficacy, making patient subjective experiences a key measurement standard [5][8]. - In the trial, 44.1% of the 152 NPC patients achieved social reintegration, and 51.3% reported satisfaction with their current life, indicating a significant impact of treatment on their overall well-being [10]. - The findings suggest that interventions targeting speech, swallowing, and appetite may enhance recovery outcomes for NPC patients, as these factors are linked to successful social reintegration and overall quality of life [10].